Results 71 to 80 of about 22,409 (253)
Olaparib‐associated cutaneous vasculitis in a patient with breast cancer
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca +3 more
wiley +1 more source
Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis
ACR Open Rheumatology, Volume 8, Issue 3, March 2026.Objective Immune checkpoint inhibitors (ICIs) are effective cancer therapies but often cause serious immune‐related adverse events (irAEs). Patients with preexisting autoimmune diseases, including vasculitis, are excluded from trials. We aimed to evaluate the frequency, severity, and outcomes of vasculitis flares and irAEs in this population.
Juan Sevillano +4 more
wiley +1 more source
Spontaneous Retroperitoneal Hematoma: A Rare Presentation of Polyarteritis Nodosa
Journal of Investigative Medicine High Impact Case Reports, 2019 Spontaneous retroperitoneal hematoma is a rare clinical entity that is most commonly caused by renal tumors and vascular disease. In this article, we present a case of spontaneous retroperitoneal hemorrhage caused by polyarteritis nodosa in a patient who
Asad Ullah MD +4 more
doaj +1 more source
Advanced Science, Volume 13, Issue 14, 9 March 2026.This schematic integrates the eight statistically significant causal relationships identified between 1,366 brain imaging‐derived phenotypes (IDPs) and 18 autoimmune inflammatory diseases (AIDs). Arrows indicate the direction of causality inferred from bidirectional two‐sample MR analyses.
Jinbin Chen +8 more
wiley +1 more source
The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab
Internal medicine, 2017 Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments.
S. Matsuo +9 more
semanticscholar +1 more source
Childhood polyarteritis nodosa: A rare presentation
Asian Journal of Medical Sciences, 2016 Polyarteritis nodosa (PAN) is a rare systemic vasculitis characterized by necrotizing arteritis of small to medium-sized arteries. It manifests as skin ulceration, hypertension, abdominal pain, digital gangrene, subcutaneous nodules etc.
Sandeep Lahiry
doaj +1 more source
Advanced Science, Volume 13, Issue 14, 9 March 2026.This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi +8 more
wiley +1 more source
Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
Arthritis &Rheumatology, Volume 78, Issue 3, Page 734-742, March 2026.Objective Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 ...
Jian Yue +55 more
wiley +1 more source
Cutaneous polyarteritis nodosa
British Journal of Dermatology, 2002 Classic polyarteritis nodosa (PAN) is a segmentary leucocytoclastic vasculitis that affects small- and medium-sized arteries. In 1931, Lindberg (Acta Med Scand 1931; 76: 183-225) described the existence of a cutaneous variant of PAN, without visceral involvement and with a more favourable prognosis. We present four patients diagnosed with cutaneous PAN
España, A. (Agustín) +2 more
openaire +3 more sources
Arthritis &Rheumatology, Volume 78, Issue 3, Page 654-664, March 2026.Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear.
Derin Karacabeyli +4 more
wiley +1 more source